CStone Out-licenses China Rights for PD-1 to Pfizer in $480 Million Deal

Suzhou CStone Pharma formed a partnership with Pfizer for China commercialization of CStone's PD-1 candidate, sugemalimab. In return for a $200 million investment in CStone, Pfizer will in-license China rights to the candidate. The $200 million will purchase a 10% stake in CStone. Also, CStone will be eligible for up to $280 million in milestones, plus royalties. In addition, the two companies will seek to bring other oncology assets to China . More details.... Stock Symbols: (HK: 2616) (NYSE: PFE) Share this with colleagues: // //